



## **Great Lakes Pharmaceuticals, Inc. Receives Fast Track SBIR Grant award from NIH**

Beachwood, Ohio - Jun 30, 2008 ([PRN](#)): Great Lakes Pharmaceuticals, Inc. announced today that the company has received Phase One, \$ 100,000 Fast Track Small Business Innovative Research (SBIR) grant from the National Institute of Health (NIH). The Phase Two of the Fast Track Award of \$2.7 M will become available to GL Pharmaceuticals upon completion of Phase I which is expected in early 2009. The grant will help fund development of antimicrobial and antithrombotic catheter lock solution.

“We are grateful to NIH for the funding which signifies medical and social importance of a product that can prevent catheter related infections and catheter occlusion .” said Krzysztof Appelt, Ph.D, the Great Lakes Pharmaceuticals’ President and CEO. “The NIH funding, together with recently closed Series A investment of \$2.4 M will help us to accelerate the clinical development of this important product. “Trials of B-Lock™, our antimicrobial and antithrombotic catheter lock solution will be initiated at eight clinical sites in 2009.

Great Lakes Pharmaceuticals expects to bring to market a safe, heparin-free, catheter lock solution with antimicrobial and antithrombotic properties designed to address the pressing problem of catheter-related bloodstream infections (“CRBSI”). Central venous catheters facilitate the administration of various therapeutic agents and collection of blood samples. The use of catheters, however, is often associated with infections and catheter occlusion. Centers for Disease Control and Prevention estimated annual occurrence of CRBSI cases at 250,000 with the cost to the healthcare system of approximately \$4.6 billion and with additional immeasurable suffering of the patients.

“This NIH grant notification came at the right time” said Professor Mahmoud Ghannoum, Chief Scientific Officer at Great Lakes Pharmaceuticals. “Our research shows that B-Lock™ eradicates all forms of microbial growth from within a venous catheter, both in vitro and in animal models. That includes elimination of mature biofilm which recently has been associated with CRBSI. No product in the market or described in the literature matches the effectiveness of B-Lock™. In addition recently reported problems with contamination of heparin emphasize the need for safe and effective catheter lock solution. B-Lock™ gives the medical profession a chance to establish a new standard of care with regard to catheter maintenance.”



## **About Great Lakes Pharmaceuticals, Inc.**

Organized in Cleveland, Ohio in 2005, privately held Great Lakes Pharmaceuticals, Inc. is a development and commercialization company focused on products designed to eliminate infections associated with indwelling venous catheters. Great Lakes Pharmaceuticals has experienced management team, and has substantial R&D collaboration with the MD Anderson Cancer Center, University of Texas, Houston and Case Western Reserve University and University Hospitals of Cleveland. The Company has recently closed a \$2.4M Series A financing. To learn more about Great Lakes Pharmaceuticals, Inc., please visit: <http://www.glpharma.com>.

### **For more information, contact:**

Krzysztof Appelt, Ph.D.

President and CEO

(760) 840-0572

Email: [kappelt@glpharma.com](mailto:kappelt@glpharma.com)

Website: <http://www.glpharma.com>